Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Signing Ceremony of the "PARAMED Project"

 
Signing Ceremony of the "PARAMED Project": A Vital Reinforcement of the Public Health Sector in Lebanon
 

Under the patronage of H.E. Dr. Firass El Abiad, Mnister of Public Health, and in the presence of a delegation from the French Ministry of Health, an official signing ceremony for the "Project for Supporting the Healthcare Personnel Skills in the Public Sector in Lebanon (PARAMED)" took place in the conference room of the Ministry of Public Health (MOPH) in Jnah.  .

This project, co-financed by Agence Française de Developpement (AFD) and the IF! Foundation, and implemented by the European Institute for Cooperation and Development (IECD), aims to substantially strengthen the skills of healthcare professionals within Lebanon's public health structures.

In his speech, the Minister of Public Health, Dr. Firas El Abiad, emphasized: "The importance of this program lies in its expansion to include 12 public hospitals, after initially starting with four hospitals, with the aim of training healthcare professionals so they can provide the necessary services to our citizens, especially the most vulnerable segments of Lebanese society. This program is funded by the French Development Agency to the tune of six million euros and is implemented by the European Institute for Cooperation and Development in Lebanon." Minister Abiad continued by stating that: “This program would not have been possible without the support provided by France to Lebanon, particularly through the French Development Agency (AFD), which supports several projects in the health and education sectors. What is remarkable about this program is that it brings together the health and education sectors, with the goal of providing better healthcare services to all people on Lebanese territory.”

Mrs. Catherine Bonnaud, Country Director and Regional Director of AFD, declared that by investing in training and professional development of health workers, we strengthen not only individual capabilities, but also the resilience and effectiveness of the health system as a whole. This is a long-term investment in the health and well-being of all Lebanese citizens.

In a context of crisis affecting the Lebanese healthcare system, the PARAMED project represents a crucial initiative to improve the quality of care provided to the most vulnerable populations and facilitate access to it. The project includes, among other objectives, the establishment of training centers in 12 public hospitals and the implementation of ongoing training and refresher programs for recent graduates and existing hospital staff.
 
Mr. Vianney Basse, Director for Lebanon and the Middle East at IECD, emphasized the quality of the trust-based relationship between the Minister of Health, AFD, and IECD, and that this partnership is fully aligned with the Ministry’s 2030 Strategy. He recalled that IECD, whose mission is to support youth through vocational training projects, will strengthen its involvement in the health sector through PARAMED.

By strengthening the capacities of health professionals and promoting the employability of young men and women in the field of nursing, the PARAMED project aims to reach 4,200 healthcare workers and approximately 3 million patients. In doing so, it will help reduce gaps and improve the quality of healthcare in Lebanon.
    1
ATC Name B/G ↑ Ingredients Dosage Form Price
J07CA09 HEXASIIL VACCINE (DIPHTERIA, TETANUS, PERTUSSIS, HEPATITIS B, POLIO, HAEMOPHILUS INFLUENZA TYPE B) Diphteria Toxoid - ?30IU/0.5ml, Tetanus toxoid - ?40IU/0.5ml, Bordetella pertussis (Whole cell) - ?4IU/0.5ml, Hepatitis B, surface antigen - 15mcg/0.5ml, Polio virus inactivated type 1 (Mahoney strain) - 40D antigen units/0.5ml, Polio virus inactivated type 2 (MEF-I strain) - 8D antigen units/0.5ml, Polio virus inactivated type 3 (Saukett strain) - 32D antigen units/0.5ml, H. Influenza type b polysaccharide1 ,2 - 10mcg/0.5ml, 1 conjugated to tetanus protein - 19-33mcg, 2 adsorbed on aluminium hydroxide hydrated, Al+++ - ?1.25mg Injectable suspension 3,594,779 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution L.L
L01CE01 HYCAMTIN IV B Topotecan HCl - 4mg 4mg Injectable lyophilised powder for solution 52,580,031 L.L
L01CE01 HYCAMTIN IV B Topotecan HCl - 4mg 4mg Injectable lyophilised powder for solution 52,580,031 L.L
N02BE51 HUMEXLIB PARACETAMOL CHLORPHENAMINE B Paracetamol - 500mg, Chlorphenamine maleate - 4mg Capsule 598,010 L.L
N02BE51 HUMEX RHUME B Pseudoephedrine HCl (tablet) - 60mg, Paracetamol (tablet) - 500mg, Paracetamol (capsule) - 500mg, Chlorphenamine maleate (capsule) - 4mg Tablet, capsule 467,657 L.L
C03BA04 HYGROTON B Chlortalidone - 50mg 50mg Tablet 422,351 L.L
A07XA04 HIDRASEC INFANTS B Racecadotril - 10mg 10mg Granules for suspension 858,715 L.L
A07XA04 HIDRASEC B Racecadotril - 100mg 100mg Capsule, hard 411,216 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution 18,792,549 L.L
M09AX01 HYALGAN B Hyaluronic acid (sodium) - 20mg/2ml 20mg/2ml Injectable solution 3,407,985 L.L
J07BC02 HAVRIX '1440' B Hepatitis A, inactivated, whole virus - 1,440 ELISA units/ml 1,440 ELISA units/ml Injectable suspension 2,215,996 L.L
J07BC02 HAVRIX JUNIOR 720 B Hepatitis A, inactivated, whole virus - 720 ELISA units/0.5ml 720 ELISA units/0.5ml Injectable suspension 1,491,665 L.L
C09DA01 HYZAAR B Losartan potassium - 100mg, Hydrochlorothiazide - 12.5mg Tablet 1,740,596 L.L
L01AA06 HOLOXAN B Ifosfamide - 1g 1g Injectable powder for solution L.L
L01AA06 HOLOXAN B Ifosfamide - 1g 1g Injectable powder for solution 3,586,850 L.L
L01AA06 HOLOXAN B Ifosfamide - 1g 1g Injectable powder for solution 3,586,716 L.L
R02AA20 HEXASPRAY COLLUTOIRE PRESSURISE B Biclotymol - 750mg 750mg Spray 353,431 L.L
H02AB09 HYDROCORTISONE ROUSSEL B Hydrocortisone - 10mg 10mg Tablet, scored 260,705 L.L
B02BD06 HAEMATE P BioHuman Von Willebrand Factor - 1200IU, Blood Coagulation Factor VIII - 500IU Injectable lyophilised powder for solution+diluent L.L
B02BB01 HAEMOCOMPLETTAN P BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution 41,515,083 L.L
B02BD06 HAEMATE P BioHuman Von Willebrand Factor - 1200IU, Blood Coagulation Factor VIII - 500IU Injectable lyophilised powder for solution+diluent 35,032,787 L.L
B02BB01 HAEMOCOMPLETTAN P BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution L.L
J06BA02 HIZENTRA 1G BioHuman Immunoglobulin human - 1g/5ml 20% Injectable solution 9,968,705 L.L
J06BA02 HIZENTRA 2G BioHuman Immunoglobulin human - 2g/10ml 20% Injectable solution 19,038,230 L.L
J06BA02 HIZENTRA 4G BioHuman Immunoglobulin human - 4g/20ml 20% Injectable solution 34,237,996 L.L
B05AA01 HUMAN ALBUMIN "OCTAPHARMA" 20% BioHuman Albumin human - 20% 20% Injectable solution 4,863,366 L.L
B05AA01 HUMAN ALBUMIN 20% SOLUTION BioHuman Albumin human - 20% 20% Injectable solution 4,343,343 L.L
B05AA01 HUMAN ALBUMIN BEHRING 20%, LOW SALT BioHuman Albumin human - 20% 20% Injectable solution 4,343,343 L.L
L04AB04 HUMIRA BioTech Adalimumab - 40mg/0.4ml 40mg/0.4ml Injectable solution L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026